SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3d 11h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat and FDA feedback are positive signals, but the cash runway of under one year makes a near-term financing event likely. Monitor for capital raise announcements or partnership deals to extend runway.

DirectionNeutral
Confidencehigh
Horizonweeks

fasedienol

▼ Bearish Named in this press release
Impact
Phase
Phase 3 (completed — two of three Phase 3 trials failed)
Time to market
Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
Next catalyst
None dated

What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs. $19.4M a year ago), with EPS of -$0.24 beating the -$0.38 consensus. The company highlighted FDA feedback on a potential Phase 3 path for fasedienol in social anxiety disorder, but cash runway is limited to about one year, raising financing risk.

Key Financial Metrics

EPS
−$0.24
est −$0.38 · +36.8%
Revenue
$138.0K
est $250.0K · -44.8% · -46.5% YoY
Rating
in line

Key Facts

  • Net loss narrowed to $10.7M from $19.4M YoY, driven by lower R&D spend ($6.6M vs $15.9M).
  • EPS of -$0.24 beat consensus of -$0.38 (36.8% surprise).
  • Cash, equivalents, and marketable securities totaled $20.0M as of Sep 30, 2026, expected to fund operations into 2027 but not beyond one year.
  • FDA provided constructive feedback on a potential Phase 3 study of fasedienol in social anxiety disorder, including use of LSAS as primary endpoint.
  • Company appointed Douglas J. Williamson, MD to the board.
  • Revenue was $138K (sublicense/other), down from $258K YoY.

Financial Impact

Net loss improved by $8.7M YoY; cash burn rate suggests ~$10M per quarter, leaving ~2 quarters of runway.

net losscash positionR&D expense

Risk Factors

  • Cash runway insufficient to fund operations beyond ~1 year; likely need for equity financing or partnership.
  • Fasedienol regulatory path remains uncertain despite FDA feedback; no guarantee of approval.
  • Revenue is negligible; company is pre-commercial with no approved products.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402954

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Viewing Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026